| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Transfusion | 13 | 2024 | 309 | 2.300 |
Why?
|
| Anticoagulants | 11 | 2024 | 592 | 1.700 |
Why?
|
| Cardiac Surgical Procedures | 9 | 2024 | 1111 | 1.320 |
Why?
|
| Blood Preservation | 4 | 2021 | 29 | 1.140 |
Why?
|
| Blood Loss, Surgical | 4 | 2024 | 152 | 1.100 |
Why?
|
| Heparin | 7 | 2024 | 229 | 1.080 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2015 | 263 | 1.010 |
Why?
|
| Blood Platelets | 4 | 2024 | 327 | 0.950 |
Why?
|
| Postoperative Hemorrhage | 6 | 2024 | 85 | 0.940 |
Why?
|
| Perioperative Care | 3 | 2023 | 196 | 0.910 |
Why?
|
| Rivers | 1 | 2023 | 9 | 0.850 |
Why?
|
| Heart-Assist Devices | 9 | 2023 | 1053 | 0.790 |
Why?
|
| Thrombocytopenia | 4 | 2019 | 227 | 0.720 |
Why?
|
| Blood Coagulation | 5 | 2018 | 122 | 0.710 |
Why?
|
| Factor VIII | 2 | 2017 | 45 | 0.670 |
Why?
|
| Bacteriological Techniques | 1 | 2019 | 86 | 0.640 |
Why?
|
| Immunoassay | 1 | 2019 | 130 | 0.640 |
Why?
|
| Platelet-Rich Plasma | 1 | 2019 | 15 | 0.640 |
Why?
|
| Hemodynamics | 2 | 2023 | 850 | 0.630 |
Why?
|
| Hemorrhage | 2 | 2018 | 468 | 0.590 |
Why?
|
| Fibrinogen | 3 | 2017 | 153 | 0.570 |
Why?
|
| Hemostatic Techniques | 1 | 2017 | 32 | 0.550 |
Why?
|
| Hemostatics | 1 | 2017 | 57 | 0.540 |
Why?
|
| von Willebrand Factor | 1 | 2017 | 196 | 0.510 |
Why?
|
| Jehovah's Witnesses | 1 | 2015 | 15 | 0.500 |
Why?
|
| Standard of Care | 1 | 2016 | 130 | 0.500 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 124 | 0.480 |
Why?
|
| Health Care Costs | 1 | 2015 | 371 | 0.400 |
Why?
|
| Blood Coagulation Factors | 2 | 2012 | 35 | 0.400 |
Why?
|
| Coronary Artery Bypass | 4 | 2004 | 514 | 0.350 |
Why?
|
| Humans | 57 | 2024 | 124802 | 0.330 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 200 | 0.320 |
Why?
|
| Plasma | 3 | 2021 | 98 | 0.300 |
Why?
|
| Erythrocyte Transfusion | 4 | 2015 | 129 | 0.290 |
Why?
|
| Cardiopulmonary Bypass | 5 | 2019 | 349 | 0.290 |
Why?
|
| Platelet Function Tests | 1 | 2006 | 40 | 0.270 |
Why?
|
| Platelet Transfusion | 3 | 2021 | 53 | 0.270 |
Why?
|
| Thoracic Surgery | 1 | 2008 | 158 | 0.260 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2024 | 628 | 0.250 |
Why?
|
| Societies, Medical | 2 | 2024 | 689 | 0.250 |
Why?
|
| Hemoglobins | 5 | 2021 | 303 | 0.230 |
Why?
|
| Shock, Cardiogenic | 2 | 2021 | 193 | 0.220 |
Why?
|
| Thrombelastography | 1 | 2024 | 57 | 0.210 |
Why?
|
| Plasma Exchange | 2 | 2018 | 84 | 0.210 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 218 | 0.200 |
Why?
|
| Blood Transfusion, Autologous | 2 | 2019 | 34 | 0.190 |
Why?
|
| Blood Component Transfusion | 1 | 2021 | 55 | 0.180 |
Why?
|
| Monitoring, Intraoperative | 1 | 2021 | 127 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2013 | 1196 | 0.170 |
Why?
|
| Platelet Factor 4 | 3 | 2016 | 22 | 0.170 |
Why?
|
| Plasmapheresis | 1 | 2019 | 29 | 0.170 |
Why?
|
| Time Factors | 7 | 2017 | 6311 | 0.170 |
Why?
|
| Administration, Oral | 2 | 2018 | 683 | 0.160 |
Why?
|
| Thrombosis | 2 | 2019 | 522 | 0.160 |
Why?
|
| Workflow | 1 | 2019 | 117 | 0.160 |
Why?
|
| Tissue Donors | 2 | 2012 | 488 | 0.160 |
Why?
|
| Antifibrinolytic Agents | 2 | 2011 | 35 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 68 | 0.150 |
Why?
|
| Ticlopidine | 2 | 2011 | 28 | 0.150 |
Why?
|
| Erythropoietin | 2 | 2009 | 104 | 0.140 |
Why?
|
| Administration, Topical | 1 | 2017 | 141 | 0.140 |
Why?
|
| Hemagglutinins | 1 | 2016 | 23 | 0.130 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2016 | 26 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 267 | 0.130 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2016 | 28 | 0.130 |
Why?
|
| Vascular Access Devices | 1 | 2016 | 35 | 0.130 |
Why?
|
| Hyperthermia, Induced | 1 | 2016 | 47 | 0.130 |
Why?
|
| Embolism, Amniotic Fluid | 1 | 2016 | 31 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2018 | 12341 | 0.130 |
Why?
|
| Bacteria | 1 | 2019 | 485 | 0.130 |
Why?
|
| Hematologic Tests | 1 | 2015 | 35 | 0.130 |
Why?
|
| Factor Xa Inhibitors | 2 | 2018 | 65 | 0.120 |
Why?
|
| Middle Aged | 18 | 2024 | 26727 | 0.120 |
Why?
|
| Preoperative Care | 2 | 2008 | 351 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 692 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 633 | 0.120 |
Why?
|
| Aged | 13 | 2024 | 19693 | 0.120 |
Why?
|
| Anemia | 2 | 2009 | 340 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 1943 | 0.110 |
Why?
|
| Female | 25 | 2024 | 66575 | 0.110 |
Why?
|
| Antithrombins | 2 | 2011 | 56 | 0.100 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2013 | 41 | 0.100 |
Why?
|
| Male | 23 | 2024 | 61302 | 0.100 |
Why?
|
| Blood Safety | 1 | 2012 | 4 | 0.100 |
Why?
|
| Bone Marrow | 2 | 2011 | 325 | 0.100 |
Why?
|
| Factor VII | 1 | 2012 | 15 | 0.100 |
Why?
|
| Freezing | 1 | 2012 | 28 | 0.100 |
Why?
|
| Personnel Selection | 1 | 2013 | 61 | 0.100 |
Why?
|
| Factor V | 1 | 2012 | 18 | 0.100 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 122 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2012 | 73 | 0.100 |
Why?
|
| Perfusion | 1 | 2013 | 203 | 0.100 |
Why?
|
| National Health Programs | 1 | 2011 | 19 | 0.100 |
Why?
|
| Hypothermia, Induced | 1 | 2013 | 166 | 0.090 |
Why?
|
| Temperature | 1 | 2012 | 305 | 0.090 |
Why?
|
| Coagulants | 1 | 2011 | 7 | 0.090 |
Why?
|
| Hemostasis, Surgical | 1 | 2011 | 37 | 0.090 |
Why?
|
| Heart Failure | 4 | 2009 | 2302 | 0.090 |
Why?
|
| Vitamin K | 1 | 2011 | 37 | 0.090 |
Why?
|
| Transplantation | 1 | 1991 | 27 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 661 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2143 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2016 | 518 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 578 | 0.090 |
Why?
|
| Laboratories | 1 | 1991 | 82 | 0.090 |
Why?
|
| Warfarin | 1 | 2011 | 119 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 768 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2012 | 383 | 0.080 |
Why?
|
| Aspirin | 1 | 2011 | 226 | 0.080 |
Why?
|
| Platelet Activation | 1 | 2009 | 71 | 0.080 |
Why?
|
| Cell Communication | 1 | 2009 | 167 | 0.080 |
Why?
|
| Risk Factors | 5 | 2018 | 10272 | 0.080 |
Why?
|
| Congresses as Topic | 3 | 2016 | 174 | 0.080 |
Why?
|
| Aorta, Thoracic | 1 | 2013 | 528 | 0.080 |
Why?
|
| Erythrocyte Aging | 2 | 1986 | 8 | 0.070 |
Why?
|
| Leukocytes | 1 | 2009 | 206 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2015 | 3436 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1989 | 138 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 578 | 0.070 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 462 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1989 | 183 | 0.070 |
Why?
|
| Erythrocytes | 2 | 1986 | 214 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 606 | 0.070 |
Why?
|
| Bloodletting | 3 | 1989 | 4 | 0.070 |
Why?
|
| Blood Donors | 2 | 2021 | 62 | 0.060 |
Why?
|
| ABO Blood-Group System | 1 | 1986 | 66 | 0.060 |
Why?
|
| Isoantibodies | 1 | 1986 | 71 | 0.060 |
Why?
|
| Adult | 11 | 2024 | 29482 | 0.060 |
Why?
|
| Dalteparin | 1 | 2005 | 6 | 0.060 |
Why?
|
| Plasminogen Activators | 1 | 2005 | 20 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 182 | 0.060 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1984 | 14 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2005 | 90 | 0.060 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 1984 | 28 | 0.060 |
Why?
|
| Fetal Monitoring | 1 | 1984 | 56 | 0.060 |
Why?
|
| Pediatrics | 1 | 2013 | 1155 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 113 | 0.060 |
Why?
|
| Drug Monitoring | 1 | 2005 | 170 | 0.050 |
Why?
|
| Cell Separation | 1 | 1984 | 229 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 173 | 0.050 |
Why?
|
| Prosthesis Implantation | 1 | 2005 | 144 | 0.050 |
Why?
|
| Retrospective Studies | 7 | 2024 | 16290 | 0.050 |
Why?
|
| Case Management | 1 | 2003 | 20 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1989 | 538 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 210 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2013 | 1178 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2005 | 178 | 0.050 |
Why?
|
| Length of Stay | 2 | 2015 | 1309 | 0.050 |
Why?
|
| Platelet Aggregation | 2 | 2009 | 121 | 0.050 |
Why?
|
| Blood Banks | 1 | 2021 | 13 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 2903 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 22 | 0.050 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 435 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2021 | 43 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 634 | 0.050 |
Why?
|
| Reoperation | 2 | 2013 | 833 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2008 | 862 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 1986 | 638 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2021 | 61 | 0.040 |
Why?
|
| United States | 3 | 2024 | 10875 | 0.040 |
Why?
|
| Anemia, Sickle Cell | 1 | 1984 | 339 | 0.040 |
Why?
|
| Differential Threshold | 1 | 1999 | 11 | 0.040 |
Why?
|
| Fetal Diseases | 1 | 1984 | 446 | 0.040 |
Why?
|
| Blood Coagulation Tests | 4 | 2005 | 61 | 0.040 |
Why?
|
| Logistic Models | 2 | 2015 | 1810 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1351 | 0.040 |
Why?
|
| Morbidity | 1 | 1999 | 244 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 1394 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2008 | 35 | 0.040 |
Why?
|
| Algorithms | 2 | 2004 | 1616 | 0.040 |
Why?
|
| Health Surveys | 1 | 1999 | 245 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 398 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1425 | 0.040 |
Why?
|
| Rivaroxaban | 1 | 2018 | 55 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 499 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 1402 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 3728 | 0.030 |
Why?
|
| Hirudins | 2 | 2008 | 37 | 0.030 |
Why?
|
| Stroke | 2 | 2018 | 984 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2015 | 19 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2008 | 214 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 64 | 0.030 |
Why?
|
| Monitoring, Physiologic | 2 | 1991 | 365 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 181 | 0.030 |
Why?
|
| Prothrombin Time | 3 | 2008 | 36 | 0.030 |
Why?
|
| Hemodilution | 1 | 1994 | 15 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 834 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 600 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 3 | 2008 | 47 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 1995 | 121 | 0.030 |
Why?
|
| Fibrinolysis | 1 | 1994 | 40 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1995 | 778 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 2015 | 141 | 0.030 |
Why?
|
| Mortality | 1 | 2015 | 237 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 549 | 0.030 |
Why?
|
| Pulmonary Artery | 3 | 2006 | 440 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 1994 | 103 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 585 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 384 | 0.020 |
Why?
|
| Calcium | 2 | 2005 | 1099 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 677 | 0.020 |
Why?
|
| Cyclosporins | 1 | 1991 | 74 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1894 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 1991 | 148 | 0.020 |
Why?
|
| Hypothermia | 1 | 1990 | 56 | 0.020 |
Why?
|
| Pregnancy | 3 | 2016 | 7172 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2013 | 435 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 4786 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 70 | 0.020 |
Why?
|
| P-Selectin | 1 | 2009 | 78 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 80 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1267 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 323 | 0.020 |
Why?
|
| Blood Specimen Collection | 1 | 1989 | 49 | 0.020 |
Why?
|
| Hemostasis | 1 | 1989 | 69 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1991 | 296 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1989 | 145 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2008 | 8 | 0.020 |
Why?
|
| Graft Survival | 1 | 1991 | 532 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 1988 | 69 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 5153 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2008 | 75 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2013 | 1025 | 0.020 |
Why?
|
| Citrates | 1 | 1987 | 22 | 0.020 |
Why?
|
| Pregnancy, Ectopic | 1 | 1987 | 23 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1999 | 3067 | 0.020 |
Why?
|
| Bilirubin | 1 | 2008 | 123 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1017 | 0.020 |
Why?
|
| HIV | 1 | 1988 | 180 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 1987 | 78 | 0.020 |
Why?
|
| Monocytes | 1 | 2009 | 354 | 0.020 |
Why?
|
| Graft Rejection | 1 | 1991 | 590 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 803 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1987 | 141 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 235 | 0.020 |
Why?
|
| Liver Transplantation | 2 | 1987 | 1038 | 0.020 |
Why?
|
| Aminocaproic Acid | 1 | 2006 | 4 | 0.020 |
Why?
|
| Aprotinin | 1 | 2006 | 11 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 1987 | 156 | 0.020 |
Why?
|
| Arterioles | 1 | 2006 | 28 | 0.020 |
Why?
|
| Creatinine | 1 | 2008 | 390 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 4615 | 0.020 |
Why?
|
| Hematinics | 1 | 2006 | 55 | 0.020 |
Why?
|
| Capillaries | 1 | 2006 | 66 | 0.020 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2006 | 44 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 1498 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1284 | 0.020 |
Why?
|
| Factor Xa | 1 | 2005 | 17 | 0.020 |
Why?
|
| Dextrans | 1 | 2005 | 45 | 0.010 |
Why?
|
| Peptide Fragments | 2 | 2005 | 779 | 0.010 |
Why?
|
| Pyruvate Kinase | 1 | 1984 | 9 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6522 | 0.010 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2006 | 312 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1984 | 250 | 0.010 |
Why?
|
| Bradycardia | 1 | 1984 | 59 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 2004 | 159 | 0.010 |
Why?
|
| Fetal Heart | 1 | 1984 | 117 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 2819 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2006 | 366 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1989 | 1237 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 3144 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 342 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2006 | 481 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 1162 | 0.010 |
Why?
|
| Thrombin Time | 2 | 1990 | 4 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2005 | 1348 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 1492 | 0.010 |
Why?
|
| Hospitalization | 1 | 2006 | 1781 | 0.010 |
Why?
|
| Neoplasms | 1 | 2011 | 2789 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1995 | 27 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2004 | 6138 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1995 | 395 | 0.010 |
Why?
|
| Adolescent | 2 | 1988 | 19330 | 0.010 |
Why?
|
| Fibrinopeptide A | 1 | 1989 | 1 | 0.010 |
Why?
|
| Fibrinopeptide B | 1 | 1989 | 1 | 0.010 |
Why?
|
| beta-Thromboglobulin | 1 | 1989 | 4 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 276 | 0.000 |
Why?
|
| Culdoscopy | 1 | 1987 | 1 | 0.000 |
Why?
|
| Ultrasonics | 1 | 1987 | 37 | 0.000 |
Why?
|
| Hypocalcemia | 1 | 1987 | 37 | 0.000 |
Why?
|
| Femoral Artery | 1 | 1987 | 194 | 0.000 |
Why?
|
| Blood Gas Analysis | 1 | 1983 | 83 | 0.000 |
Why?
|
| Positive-Pressure Respiration | 1 | 1983 | 82 | 0.000 |
Why?
|
| Intraoperative Care | 1 | 1983 | 104 | 0.000 |
Why?
|
| Body Temperature | 1 | 1983 | 115 | 0.000 |
Why?
|
| Urinary Catheterization | 1 | 1983 | 81 | 0.000 |
Why?
|
| Laparoscopy | 1 | 1987 | 487 | 0.000 |
Why?
|
| Catheterization | 1 | 1983 | 236 | 0.000 |
Why?
|
| Liver | 1 | 1987 | 1764 | 0.000 |
Why?
|
| Texas | 1 | 1988 | 3590 | 0.000 |
Why?
|
| Cardiac Catheterization | 1 | 1983 | 631 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1988 | 8182 | 0.000 |
Why?
|
| Infant | 1 | 1988 | 12481 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1988 | 14050 | 0.000 |
Why?
|
| Child | 1 | 1988 | 24456 | 0.000 |
Why?
|